Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients

Affiliation auteurs!!!! Error affiliation !!!!
TitreInaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients
Type de publicationJournal Article
Year of Publication2018
AuteursBalloy G., Pelletier J., Suchet L., Lebrun C., Cohen M., Vermersch P., Zephir H., Duhin E., Gout O., Deschamps R., Le Page E., Edan G., Labauge P., C. Dallieres C, Rumbach L., Berger E., Lejeune P., Devos P., N'Kendjuo J.-B, Coustans M., Auffray-Calvier E., Daumas-Duport B., Michel L., Lefrere F., Laplaud D.A, Brosset C., Derkinderen P., De Seze J., Wiertlewski S., Plaques SFrancophon
JournalJOURNAL OF NEUROLOGY
Volume265
Pagination2251-2259
Date PublishedOCT
Type of ArticleArticle
ISSN0340-5354
Mots-clésBalo, Demyelinating disease, multiple sclerosis, Pseudo-tumoral form, Schilder
Résumé

Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo's concentric sclerosis, Schilder's disease and acute disseminated encephalomyelitis] with overlapping clinical presentation. The aim of our study was to better characterize these patients. Eighty-seven patients (62 women and 25 men) from different MS centers in France were studied retrospectively. Inclusion criteria were (1) a first clinical event (2) MRI showing one or more large demyelinating lesions (20 mm or more in diameter) with mass-like features. Patients with a previous demyelinating event (i.e. confirmed multiple sclerosis) were excluded. Mean age at onset was 26 years. The most common initial symptoms (67% of the patients) were hemiparesis or hemiplegia. Aphasia, headache and cognitive disturbances (i.e. atypical symptoms for demyelinating diseases) were observed in 15, 18 and 15% of patients, respectively. The mean largest diameter of the tumefactive lesions was 26.9 mm, with gadolinium enhancement in 66 patients (81%). Twenty-one patients (24%) had a single tumefactive lesion. During follow-up (median time 5.7 years) 4 patients died, 70 patients improved or remained stable and 12 worsened. 86% of patients received initial corticosteroid treatment, and 73% received disease-modifying therapy subsequently. EDSS at the end of the follow-up was 2.4 +/- 2.6 (mean +/- SD). This study provides further evidence that the clinical course of MS presenting with large focal tumor-like lesions does not differ from that of classical relapsing-remitting MS, once the noisy first relapsing occurred.

DOI10.1007/s00415-018-8984-7